Emcure Pharmaceuticals Ltd (NSE: EMCURE) and Piramal Pharma Ltd (NSE: PPLPHARMA) are both listed in the Pharmaceuticals industry. Emcure Pharmaceuticals has a market capitalisation of ₹35,726 Cr and Piramal Pharma ₹31,892 Cr, as of 9 Nov 2026. Return on equity is 19.57% for Emcure Pharmaceuticals and -4.00% for Piramal Pharma. Over one year, Emcure Pharmaceuticals's share price is up 67.0% and Piramal Pharma's is up 21.7%.
| Metric | Emcure Pharmaceuticals | Piramal Pharma |
|---|---|---|
| NSE Symbol | EMCURE | PPLPHARMA |
| BSE Code | 544210 | 543635 |
| Share Price | ₹2,215.00 | ₹245.30 |
| Market Cap | ₹35,726 Cr | ₹31,892 Cr |
| P/E Ratio | 38.6 | Not meaningful (loss) |
| Return on Equity | 19.57% | -4.00% |
| Return on Assets | 9.62% | 0.36% |
| Dividend Yield | 0.19% | 0.00% |
| Beta (1Y) | -0.01 | 0.31 |
| 1-Year Price Change | +67.0% | +21.7% |
| 3-Month Price Change | +11.0% | +14.8% |
| 52-Week Range | ₹1,312.30 – ₹2,280.00 | ₹132.30 – ₹250.40 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹2,820 Cr | ₹2,617 Cr |
| Quarterly Net Profit | ₹325 Cr | ₹5 Cr |
| Net Margin | 11.5% | 0.2% |
| EPS (Basic, Quarter) | ₹17.16 | ₹0.04 |
| Results Basis | consolidated | consolidated |
| Headquarters | Pune, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglut…
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generi…
Emcure Pharmaceuticals has a market capitalisation of ₹35,726 Cr, against ₹31,892 Cr for Piramal Pharma as of 9 Nov 2026, about 1.1 times the size by market cap.
Emcure Pharmaceuticals has a return on equity of 19.57% and Piramal Pharma -4.00%.
Emcure Pharmaceuticals's share price is up 67.0% over one year and Piramal Pharma's is up 21.7%.
Emcure Pharmaceuticals reported revenue of ₹2,820 Cr and net profit of ₹325 Cr for Q2 FY27. Piramal Pharma reported revenue of ₹2,617 Cr and net profit of ₹5 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.